Cencora (COR)
NYSE: COR · Medical Distribution · Conshohocken, PA
Our rating: Neutral
Neutral reaffirmed at $325.00, moderate conviction, August 10, 2026.
Breaks if: Turns Cautious if trailing twelve-month free cash flow falls below $2.5B at either of the next two quarterly filings — indicating the working-capital cushion is unwinding rather than persisting — or if full-year revenue growth decelerates to below 5% at the next annual report. Turns Positive if the next annual report shows free cash flow of $3.8B or more alongside revenue growth of at least 10%, indicating the specialty volume tailwind is compounding rather than plateauing.
Key figures
| Market value | $64.7B |
|---|---|
| Revenue, last 12 months | $332.8B |
| Net income, last 12 months | $2.6B |
| Free cash flow, last 12 months | $4.1B |
| Price to earnings | 24.7× |
| Free cash flow yield | 6.3% |
| Dividend yield | 0.7% |
| Operating margin | 0.9% |
| Return on equity | 104.3% |
| Beta to the S&P 500 | 0.03 |
| Volatility, annualized | 25.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| June 30, 2026 | $84.8B | 5.1% | $3.94 | $2.4B |
| March 31, 2026 | $78.4B | 3.8% | $8.40 | $1.2B |
| December 31, 2025 | $85.9B | 5.5% | $2.87 | −$2.4B |
| September 30, 2025 | $83.7B | 5.9% | $-1.74 | $2.9B |
| June 30, 2025 | $80.7B | 8.7% | $3.52 | −$74M |
| March 31, 2025 | $75.5B | 10.3% | $3.68 | $3.2B |
| December 31, 2024 | $81.5B | 12.8% | $2.50 | −$2.8B |
| September 30, 2024 | $79.1B | 14.7% | $0.04 | $818M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $88.0B: Claude 52%, Gemini 75%, Mistral 48%
- Diluted earnings per share are above zero: Claude 62%, Gemini 95%, Mistral 90%
- Free cash flow for the quarter is at least $2.88B: Claude 40%, Gemini 35%, Mistral 45%
14 ledger entries and 67 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.